SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
Also known as: AZD1222 ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca

Therapeutic indications

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for:

Active immunisation to prevent COVID-19 caused by SARS-CoV-2

Population group: both men and women, only adults (18 years old or older)

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈